OSE Immunotherapeutics reported a net loss of €37.7 million for 2025, compared to a profit of €37.4 million in 2024, mainly due to non-recurring income in the prior year. The company ended 2025 with a cash position of €22.7 million, decreasing to €17.0 million by March 2026, which is expected to fund operations until early Q4 2026. Increased R&D expenses reflect ongoing development, including the Phase 3 trial of Tedopi®. To extend its cash runway, OSE is considering strategic partnerships, equity financing, debt restructuring, and milestone payments. The filing of audited financials is postponed to May 28, 2026, pending audit completion and potential financing outcomes.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
